Literature DB >> 34855090

Cure of Mice with Advanced Ovarian Adenocarcinoma CaO1 by the Serum Blood Proteins.

F V Donenko1, S M Sitdikova2, Yu I Dolzhikova2, Yu S Lebedin3.   

Abstract

After removal of the primary tumor node, tumor-specific activity appears in the serum that blocks tumor growth in mice. This activity is observed at the time interval when activity of the tumor growth-stimulating factor is not determined. Administration of blood serum (0.1 ml) from mice with removed tumor to mice with CaO1 adenocarcinoma for 14 days led first to a stop of its growth, and then to tumor regression. The animals cured of adenocarcinoma lived for at least one year without signs of relapse. The cured animals did not develop resistance to repeated tumor transplantation. Repeated transplantation led to the growth of the new tumor. No cellular immune response was observed on histological slides of the regressing tumor. It was concluded that a serum factor is required for the growth of a tumor in the body and the state of the serum with blocked activity of this tumor-stimulating factor can be used for tumor treatment in oncology patients. This is the first result in the syngeneic system, when the tumor was cured by syngeneic serum proteins.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  blood serum proteins; removal of primary tumor; tumor cure

Mesh:

Substances:

Year:  2021        PMID: 34855090     DOI: 10.1007/s10517-021-05361-7

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  9 in total

1.  Specificity of relapses and metastases of experimental transplanted Ehrlich carcinoma and B16 melanoma.

Authors:  S M Sitdikova; B S Amandzholov; M V Kiselevskii; F V Donenko
Journal:  Bull Exp Biol Med       Date:  2007-01       Impact factor: 0.804

2.  Peculiarities of hemoglobin interaction with serum proteins of mice with Ehrlich carcinoma.

Authors:  S M Sitdikova; B S Amandzholov; M V Serebryakova; M Yu Zhdanovich; M V Kiselevskii; F V Donenko
Journal:  Bull Exp Biol Med       Date:  2006-05       Impact factor: 0.804

3.  Conformational changes in inter-α-trypsin inhibitor heavy chain 4 activate its tumor-specific activity in mice with B16 melanoma.

Authors:  Natalya G Kormosh; Tatyana V Davidova; Vladimir N Kopyltsov; Marina V Serebryakova; Aigul O Kabieva; Konstantin E Voyushin; Suriya M Sitdikova; Berick S Amandzholov; Michail V Kiselevskii; Fedor V Donenko
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

4.  Identification of serpin (alpha-1-antitrypsin) as serum growth inhibitory factor in murine ehrlich carcinoma by proteomics.

Authors:  F V Donenko; R H Ziganshin; N Yu Anisimova; K E Voyushin; S M Sitdikova; B S Amandzholov; M V Kiselevskii; T Efferth
Journal:  Cancer Genomics Proteomics       Date:  2010 May-Jun       Impact factor: 4.069

5.  Induction of resistance to murine tumor development is associated with alterations in the glycosylation of blood serum proteins.

Authors:  F V Donenko; R K Ziganshin; S M Sitdikova; B S Amandzholov; M V Kiselevskii; T Efferth
Journal:  Mol Med Rep       Date:  2009 May-Jun       Impact factor: 2.952

6.  Presence of a growth-stimulating factor in serum following primary tumor removal in mice.

Authors:  B Fisher; N Gunduz; J Coyle; C Rudock; E Saffer
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  Evaluation of immunotherapy efficiency in mouse CaO-1 ovarian carcinoma treated by vaccines based on dendritic cells.

Authors:  S M Sitdikova; M V Kiselevskii; V Yu Sel'chuk; B S Amandzholov; E A Kurbatova; F V Donenko
Journal:  Bull Exp Biol Med       Date:  2009-02       Impact factor: 0.804

8.  Hemoglobin-associated proteins isolated from blood serum of Ehrlich carcinoma-bearing mice.

Authors:  F V Donenko; S M Sitdikova; A V Syrtsev; A T Gradyushko; M V Kiselevsky; M V Serebryakova; T Efferth
Journal:  Int J Oncol       Date:  2008-04       Impact factor: 5.650

9.  [The characteristics of Ehrlich carcinoma recurrence and metastasis].

Authors:  F V Donenko; S M Sitdikova; A O Kabieva; L V Moroz
Journal:  Biull Eksp Biol Med       Date:  1992-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.